Search

News Chemoimmunotherapy in the Treatment of Breast Cancer −⁠ Final Results of the IMpassion130 Study

According to international recommendations, treatment with the immune checkpoint inhibitor atezolizumab in combination with the cytostatic nab-paclitaxel is used for patients with locally advanced or metastatic breast cancer where PD-L1 protein expression is detected on the surface of tumor-infiltrating immune cells (IC). The final results regarding overall survival and long-term safety of this treatment in patients who participated in the registration study IMpassion130 were presented at this year's European Society for Medical Oncology (ESMO) congress, which was held virtually due to circumstances.

Source: Breast Carcinoma 25. 10. 2020

News Time is Blood! Impact of Diagnostic Delays on Prognosis of Patients with Acquired Hemophilia A

The famous slogan of neurologists in connection with strokes –⁠ 'Time is brain!' –⁠ can be modified to 'Time is blood!' for the issue of acquired hemophilia A (AHA). The factor of time plays a crucial role in the prognosis of patients with AHA –⁠ delayed diagnosis is associated with longer administration of hemostatic treatment, higher risk of relapses, and mortality.

Source: Hemophilia 16. 8. 2022

News Favorable effect of linagliptin on renal endothelial functions in patients with type 2 diabetes mellitus

Diabetic nephropathy is the cause of up to 50% of cases of end-stage chronic kidney disease. The main pathological mechanism involved in the development of the early stage of diabetic nephropathy is endothelial dysfunction. The aim of the German study was to evaluate the effects of linagliptin on endothelial function in the renal vasculature.

Source: Diabetes 1. 3. 2020

News To what extent can improvement of nutritional status through parenteral nutrition affect the results of oncological treatment?

Just like cancer patients and their caregivers, doctors often overlook the risk of malnutrition. Good nutrition can be a predictor of survival in patients with malignancies.

Source: Parenteral Nutrition 14. 11. 2022

News Prevention and Treatment of Thromboembolism in the Elderly

Despite advances in the prevention and treatment of venous thromboembolism, morbidity and mortality associated with this condition remain high in certain risk groups. An international expert group focused on the elderly in its analysis published in the Thrombosis Journal.

Source: Thromboprophylaxis 9. 6. 2022

News ESC 2022: Evidence of SGLT2i Effectiveness in HFrEF Treatment is Growing: How to Integrate Them into Routine Practice?

Although the need for pharmacotherapeutic options for patients with heart failure with reduced left ventricular ejection fraction (HFrEF) is essential, challenges in implementing this medication according to guidelines persist. This issue was also discussed at a symposium held as part of this year's European Society of Cardiology Congress (ESC 2022).

Source: Heart Failure 1. 11. 2022

News Probiotics as a Helper in the Fight Against Pregnancy Gingivitis

Gingivitis is a common problem during pregnancy. In addition to quality oral hygiene, regular consumption of probiotic preparations containing certain strains of Limosilactobacillus reuteri can also help reduce or completely eliminate it.

Source: GI, colic and microbiome 2. 9. 2022

News Safety Analysis of Baricitinib in Long-Term Treatment of Rheumatoid Arthritis

Janus kinase inhibitors are relatively new and very promising drugs, but their novelty also raises the question: Are they really safe? A brand-new analysis provides the answer by examining a cohort of patients treated for the longest duration to date.

Source: Biological Treatment 21. 8. 2020

News INTERACTIVE CASE STUDY of a patient with mCRC treated long-term with various modalities

MUDr. Stanislav John, Ph.D., Clinic of Oncology and Radiotherapy, Faculty of Medicine, Charles University and University Hospital Hradec Králové

Source: Colorectal Cancer 11. 3. 2021

News Chemotherapy as a Risk Factor for Severe COVID-19 Course?

During the coronavirus pandemic, patients with malignant neoplastic diseases are considered an at-risk group. Whether chemotherapy is a risk factor for a more severe course of COVID-19 was the subject of the study presented below.

Source: Antiemetic Therapy 8. 4. 2021

News Benefit of ixazomib in patients with relapsed/refractory multiple myeloma in routine clinical practice

The results of treating relapsed or refractory multiple myeloma in real-world routine clinical practice were published by a broad team of Czech experts in the journal BMC Cancer.

Source: Hematologic Malignancies 10. 3. 2021

News News in the Treatment of Allergic Rhinitis

According to literary sources, 17–28.5% of Europeans suffer from allergic rhinitis (AR), which negatively affects the quality of daily life. Below, we summarize the new recommendations from ARIA (Allergic Rhinitis and its Impact on Asthma) from 2019 regarding the treatment of this condition and highlight a new therapeutic option offered by the fixed combination of mometasone furoate with olopatadine hydrochloride.

Source: Life Without Allergic Rhinitis 27. 4. 2022

News Contact Dermatitis in Patients with Venous Ulcers –⁠ and How to Prevent It?

The prevalence of chronic wounds increases with the rising average age, and for example, venous ulcers affect up to 2% of the global population. Materials used for wound coverage, however, present a risk for the development of contact dermatitis of allergic or irritant origin. The topic of contact dermatitis in patients with venous ulcers is covered in a review article published in the International Journal of Women’s Dermatology.

Source: Wound Healing 31. 10. 2022

Články časopisu Hepatocellular carcinoma future treatment options

Author of the article: MUDr. Tomášek Jiří, Ph.D., doc. MUDr. Kiss Igor, Ph.D. Mba Source: Klinická onkologie | Supplementum 3/2020 31. 10. 2020

News Safety of Dabigatran in Secondary Prevention of Venous Thromboembolism in Pediatric Patients

Low molecular weight heparin (LMWH) or warfarin (VKA –⁠ vitamin K antagonist) is typically used for the secondary prevention of venous thromboembolism. The DIVERSITY study extension examined the safety of dabigatran in this indication in pediatric patients.

Source: Anticoagulant Treatment 23. 2. 2022